Live Breaking News & Updates on Jorgej Castillo

Stay updated with breaking news from Jorgej castillo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia. ....

Jorgej Castillo , Dana Farber Cancer Institute , Harvard Medical School , Bing Center , Onclive Tv , Iopofosinei 131 , Waldenström Macroglobulinemia , Clover Wam ,

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy. ....

Jorgej Castillo , Harvard Medical School , Dana Farber Cancer Institute , Bing Center , Onclive Tv , Hematologic Oncology , Mash 2023 , Waldenström Macroglobulinemia , Anti Mag , Peripheral Neuropathy ,

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.
....

Jorgej Castillo , Harvard Medical School , Bing Center , Dana Farber Cancer Institute , Onclive Tv ,

Dr Castillo on Ongoing Areas of Investigation in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, discusses the ongoing investigation into potential treatment options for patients with Waldenström macroglobulinemia, including iopofosine I-131. ....

Jorgej Castillo , Fdafor Waldenstr , Pirtobrutinib Jaypirca , Harvard Medical School , Bing Center , Dana Farber Cancer Institute , Onclive Tv , Hematologic Oncology , Mash 2023 , Iopofosinei 131 , Waldenström Macroglobulinemia ,

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy ....

United States , United Kingdom , Great Britain , Emily Collins , Emmanuel Bachy , Bijald Shah , Lai Wang , Christian Buske , Felipe Samaniego , Jake Shortt , Kevin Mannix , Mazyar Shadman , Jorgej Castillo , Paolo Ghia , Constantine Tam , Ibrutinib Monotherapy , Alessandra Tedeschi , Constantines Tam , European Hematology Association , Drug Administration , Exchange Commission , Global Head Of Research Development At Beigene , European Union , Network Meta , Bristol Myers Squibb , A Bayesian Network Meta ,